eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


3/2020
vol. 7
 
Share:
Share:
more
 
 
abstract:
Review paper

The management of allergic diseases in children during the SARS-CoV-2 pandemic

Marcin Baut
1
,
Jadwiga Biela-Mazur
1
,
Anna Czyżewska-Dudek
1
,
Ryszard Kurzawa
1, 2

1.
Klinika Alergologii i Pneumonologii, Instytut Gruźlicy i Chorób Płuc, Odział Terenowy w Rabce-Zdroju, Polska
2.
Instytut Nauk o Zdrowiu, Kosmetologia, Podhalańska Państwowa Uczelnia Zawodowa w Nowym Targu, Polska
Alergologia Polska – Polish Journal of Allergology 2020; 7, 3: 153–161
Online publish date: 2020/07/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The article presents and summarizes the current state of knowledge about the management and treatment of allergic diseases in children during the SARS-CoV-2 pandemic. Patients with allergic diseases do not show different symptoms of COVID-19. Children with atopy, like most children, undergo this infection mildly. Current recommendations of Polish and international societies recommend continuing the therapy of allergic diseases to minimize the adverse effects of discontinuing treatment. Continuing treatment with inhaled and oral glucocorticosteroids, antihistamines and anti-leukotriene drugs is not a risk factor for SARS-CoV-2 infection and should not be stopped. Effective treatment of allergic rhinitis may have a positive effect on reducing the transmission of the virus. For children with atopic dermatitis it is essential to use barrier preparations to care atopic skin more often to minimize side effects of excessive use of soaps and disinfectant fluids. It is not recommended to start immunotherapy with inhaled allergens during a pandemic. If there are conditions for epidemiologically safe continuation of specific immunotherapy, the sublingual form is preferred. To minimize the risk of transmission of SARS-CoV-2 infection in medical facilities, telemedicine is the preferred method for continuing specialist care.
keywords:

SARS-CoV-2, coronavirus, COVID-19, allergic diseases

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe